Overview

Pola-R2 in Newly Diagnosed Non-fit Elderly DLBCL Patients

Status:
Recruiting
Trial end date:
2027-10-24
Target enrollment:
Participant gender:
Summary
This is a prospective, single-arm, phase II study, and the purpose of this study is to evaluate the efficacy and safety of Pola-R2 regimen in newly diagnosed elderly diffuse large B cell lymphoma classified into un-fit or frail group by comprehensive geriatric assessment(CGA).
Phase:
Phase 2
Details
Lead Sponsor:
Yan Zhang, MD
Collaborators:
Chinese PLA General Hospital
Peking University First Hospital
Peking University Third Hospital
Treatments:
Lenalidomide
Polatuzumab vedotin
Rituximab